The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis

C Mullarkey1, E Crowley2, C Martin2

  • 1Emergency Department, National Children's Hospital, Tallaght, Dublin. caitriona.mullarkey@hse.ie

Irish Medical Journal
|January 15, 2014
PubMed

Insights

Adding Ondansetron to oral rehydration therapy (ORT) significantly reduced intravenous fluid (IVF) use in pediatric emergency department patients with gastroenteritis. This intervention also decreased hospital admissions, improving patient outcomes.

Area of Science:

  • Pediatric Emergency Medicine
  • Gastroenterology
  • Pharmacology

Background:

  • Acute gastroenteritis is a common cause of dehydration in children presenting to emergency departments.
  • Oral rehydration therapy (ORT) is the standard initial treatment, but some children fail to respond.
  • Intravenous fluid (IVF) administration and hospital admission are common outcomes for refractory cases.

Purpose of the Study:

  • To evaluate the impact of adding Ondansetron to an established ORT protocol.
  • To assess changes in IVF administration and hospital admission rates.
  • To determine the effectiveness of Ondansetron in facilitating successful oral rehydration.

Main Methods:

  • A retrospective study comparing two six-week periods (2008 vs. 2009).
  • Children received standard ORT in 2008; Ondansetron was added to ORT for refractory cases in 2009.
  • Outcome measures included IVF administration rates, admission rates, and successful oral rehydration.

Main Results:

  • IVF administration decreased by 19% (40.9% in 2008 vs. 21.7% in 2009, p < 0.0001).
  • Admission rates showed a non-significant reduction of 1.6% (14.41% vs. 12.82%, p=0.62).
  • Of 34 patients receiving Ondansetron, 79% were successfully rehydrated orally.

Conclusions:

  • Ondansetron is an effective adjunct to ORT in pediatric gastroenteritis.
  • The addition of Ondansetron significantly reduces the need for intravenous fluids.
  • This strategy improves oral rehydration success rates and potentially decreases admissions.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
854
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
602
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.4K